Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Breast NeoplasmsBreast Cancer
Interventions
DRUG

Eribulin mesylate

1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days

Trial Locations (14)

410-769

National Cancer Center, Goyang-si

463-707

Seoul National University Bundang Hospital, Seongnam-si

443-380

Ajou University Hospital, Suwon

361-711

Chungbuk National University Hospital, Cheongju-si

602-715

Dong-A University Hospital, Busan

700-721

Kyungpook National University Hospital, Daegu

405-760

Gachon University Gil Medical Center, Incheon

110-744

Seoul National University Hospital, Seoul

120-752

Severance Hospital, Seoul

135-710

Samsung Medical Center, Seoul

136-705

Korea University Anam Hospital, Seoul

138-736

Asan Medical Center, Seoul

152-703

Korea University Guro Hospital, Seoul

682-714

Ulsan University Hospital, Ulsan

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT01961544 - Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer | Biotech Hunter | Biotech Hunter